<code id='D671E5E69E'></code><style id='D671E5E69E'></style>
    • <acronym id='D671E5E69E'></acronym>
      <center id='D671E5E69E'><center id='D671E5E69E'><tfoot id='D671E5E69E'></tfoot></center><abbr id='D671E5E69E'><dir id='D671E5E69E'><tfoot id='D671E5E69E'></tfoot><noframes id='D671E5E69E'>

    • <optgroup id='D671E5E69E'><strike id='D671E5E69E'><sup id='D671E5E69E'></sup></strike><code id='D671E5E69E'></code></optgroup>
        1. <b id='D671E5E69E'><label id='D671E5E69E'><select id='D671E5E69E'><dt id='D671E5E69E'><span id='D671E5E69E'></span></dt></select></label></b><u id='D671E5E69E'></u>
          <i id='D671E5E69E'><strike id='D671E5E69E'><tt id='D671E5E69E'><pre id='D671E5E69E'></pre></tt></strike></i>

          Home / explore / comprehensive

          comprehensive


          comprehensive

          author:entertainment    Page View:5529
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In